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The spectrum of tissue distribution and function of immuno-
regulatory glycoproteins has been dramatically increased in the
past ten years. Interleukin-l and granulocyte-macrophage col-
ony stimulating factor, which were originally described as
products of classic immune cells acting on restricted subsets of
target cells, are now recognized as products of a variety of
transformed and nontransformed cell types with pleiotropic
effects on several circulating and tissue cells. The expanded
paradigm of cytokine production and function has occurred as a
consequence of a methodical and occasionally fortuitous exper-
imental approach using cell culture models in vitro to provide a
basis for in vivo studies. Observations in transgenic mouse
models have also provided insights for in vitro and in vivo
studies. The first published clue that interleukin-6 (IL-6) might
have proliferative effects on glomerular cells was observed in
transgenic mice carrying the IL-6 gene fused to a human
immunoglobulin heavy chain enhancer [1]. The transgenic mice
developed high circulating levels of IL-6, polyclonal IgG1
plasmacytosis, and mesangioproliferative glomerulonephritis
[1].
The purpose of this review is to summarize the available data
from in vitro and in vivo studies which support the role of IL-6
as an autocrine regulator of mesangial cell (MC) proliferation.
To understand the potential role of IL-6 in this process, it is
important to emphasize that IL-6 is not the sole or necessarily
even the most potent regulator of MC growth, but rather
functions in the context of a cytokine network which is inher-
ently complex, redundant, and interdependent upon both inhib-
itory and stimulatory components [2].
Interleukin-6 was originally identified as a 26 kDa protein in
the culture supernatants from antigen- or mitogen-stimulated
peripheral mononuclear cells which induced immunoglobulin
production by activated B cells [3]. The human IL-6 protein is
comprised of 184 amino acids with two N-glycosylation sites.
The two disulfide bonds do not appear necessary for the
biologic activity of IL-6 [5]. The IL-6 gene contains five exons
and the major form of IL-6 mRNA is a 1.3 kb transcript.
Following its original description in monocytes, IL-6 has
been shown to be produced by B and T lymphocytes, epithelial
cells, and endothelial cells, fibroblasts, and astrocytes [3]. The
effects of IL-6 are summarized in Table 1. In addition to
inducing the growth and differentiation of a wide spectrum of
target cells, IL-6 can also inhibit the growth of certain neoplas-
tic cells [reviewed in 3, 4].
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The essential components of the intracellular signal transduc-
tion pathway triggered by IL-6 are unknown. The IL-6 receptor
has been cloned and found to contain structural homology with
the C2 set of the immunoglobulin gene receptor superfamily [5,
6]. Approximately 100 to 1000 IL-6 receptors per cell are
present on most IL-6 responsive cell types. The IL-6 receptor is
an 80 kDa protein with a single transmembrane segment (28
amino acids). The intracytoplasmic domain is comprised of 82
amino acids and lacks homology with known signal transducing
proteins. Mutant IL-6R lacking the intracytoplasmic domain
retains functional activity, which suggests that the signal trans-
ducing domain resides in another component of the receptor
complex [6]. Following binding of IL-6, the IL-6R appears to
associate with a 130 kDa membrane glycoprotein. The 130 kDa
non-ligand binding glycoprotein may play a role in initiating
signal transduction following complex formation with the IL-6R
[6].
The expression of IL-6 mRNA in total RNA preparations
from normal human kidney was first demonstrated by Tovey et
a! [7]. The investigators found approximately 0.3 copies of IL-6
mRNA transcript per kidney cell. Thereafter, workers in sev-
eral laboratories sought to determine if mesangial cells produce
IL-6 and to define the ability of IL-6 to induce MC growth in
vitro as suggested by data from the transgenic mouse model [1].
The data from observations in vitro and in vivo will be summa-
rized.
In vitro studies
The first published demonstration that cultured MCs produce
IL-6 in vitro appeared in 1989 [8]. The work of Horii et a!
demonstrated that cultured rat mesangial cells (MCs) secrete
biologically active IL-6 and contain IL-6 mRNA by northern
blot and in situ hybridization [81. Moreover, IL-6 was shown to
induce 3H-thymidine uptake by MCs cultured in the presence of
4% fetal calf serum. In comparison to other known mesangial
cell mitogens; IL-i and PDGF, IL-6 was found to be a more
potent inducer of proliferation [8].
Simultaneous studies in our own laboratory produced similar
results [4]. Cultured rat MCs were shown to produce IL-6
protein and contain IL-6 mRNA. The IL-6 bioactivity in MC
supernatant could be blocked with polyclonal anti-IL-6 anti-
body. Since IL-6 from different cell sources may have different
biochemical properties [9], we characterized the biochemical
features of MC-derived IL-6. The molecular weight of MC-IL-6
was found to be 17 to 42 kD by gel filtration HPLC and the
isoelectric point ranged from 4.0 to 5.3. These properties are
similar to those described for IL-6 from other cell sources [4].
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Table 1. Effects of interleukin-6
Induces synthesis of hepatic acute phase proteins
Induces terminal maturation of B cells
Growth of hybndoma and plasmacytoma cells
Growth of hematopoietic progenitor cells (with IL-3)
Growth and cytotoxic differentiation of T cells (with IL-i)
Inhibition of growth of some neoplastic cells
Induction of neural cell differentiation
Table 2. Soluble factors which increase interleukin-6 production by






Moreover, these data are consistent with the possibility that
MC-derived IL-6 may be comprised of a heterogeneous mixture
of isoforms with different molecular weights or isoelectric
points. In addition, both recombinant and partially-purified IL-6
were found to induce 3H-thymidine uptake and growth of MCs
in the presence of 0.5% FCS.
The ability of IL-6 to induce MC growth in 0.5% FCS in our
study contrasts with the requirement of 4% FCS in the study of
Horii et al [8]. These discrepant findings may be related to
different preparations of FCS or the use of insulin (5 /Lg/ml) in
our culture medium. Insulin might possibly synergize with IL-6
in inducing MC growth. Despite including insulin in the culture
medium, however, IL-6 did not induce MC growth in the
absence of serum [4]. Studies in T cells and hematopoictic cells
have suggested that IL-6 may act as a competence factor in
stimulating cells in G0 to enter into G1 [reviewed in 3]. The data
in mesangial cells suggest that IL-6 requires additional progres-
sion factors in serum to exert a proliferative effect in vitro.
The potency of IL-6 relative to other cytokines in inducing
growth of MCs in vitro is uncertain. The data of Horii et al [8],
suggest that IL-6 is more active than IL-i or PDGF at 72 hours.
We have compared recombinant IL-6 with PDGF, IL-I and
arginine vasopressin (AVP) with respect to their effects on
3H-thymidine uptake by MCs at several time points (24 to 192
hrs). The MCs were cultured in 0.5% FCS for these studies. In
contrast to the findings of Horii et al [8], recombinant IL-6 is
consistently less active than PDGF or AVP (Ruef and Coleman,
unpublished observations). Our data suggest that IL-6 is com-
parable to IL-i in stimulating MC growth in vitro, The different
findings may be partly attributable to the use of different
cytokine preparations or different concentrations of FCS (0.5
vs. 4.0%) during the culture period.
Since MCs are subject to autocrine and paracrine signals
which may regulate IL-6 production, investigators in several
laboratories have examined the regulation of IL-6 production
by cultured mesangial cells. The soluble factors which regulate
IL-6 production are listed in Table 2 [8, 101 (Ruef and Coleman,
unpublished observations). In addition to the factors listed in
Table 2, IL-6 production in other cell types has been shown to
be increased by interferon beta, phorbol esters, agents which
increase intracellular cAMP, and various viral infections includ-
ing human immunodeficiency virus [reviewed in 31. The sub-
stances which stimulate IL-6 production may act in an auto-
crine (IL-i, PDGF) or paracrine (LPS, TNF-a) manner to
regulate IL-6 production in the glomerulus.
The molecular mechanism whereby IL-6 production is regu-
lated in mesangial cells is uncertain. Studies in other cell types,
however, have identified functional response elements in the 5'
promoter region of the IL-6 gene [11]. Consensus sequences for
the glococorticoid response element, AP-1 binding site, cyclic
AMP response element, serum response element and NF-kappa
B binding site have been identified [3, 11]. Studies in HeLa cells
have delineated a 23-bp region of the IL-6 promoter (—173 to
—151) which confers responsiveness of a heterologous thymi-
dine kinase gene promoter to serum, PMA, IL-la, TNF and
cAMP agonists [101. The 23-bp "multiple cytokine response
element" lies within a 46-bp stretch of the IL-6 promoter which
is similar to the regulatory region of the c-fos gene [11].
Additional studies are needed to extend these observations to
mesangial cells to define enhancer and repressor elements in the
IL-6 gene.
The down regulation of IL-6 production in mesangial cells has
not been widely studied, in part because constitutive IL-6
production is low and somewhat variable between laboratories.
Glucocorticords have been shown to decrease IL-6 production
by fibroblasts [12]. Recent unpublished data from our labora-
tory have suggested that extracellular matrix components may
decrease IL-6 release. For example, mesangial cells cultured in
0.5% FCS on collagen type I exhibit a dose-dependent decrease
in both constitutive and LPS-stimulated IL-6 release (unpub-
lished observations). The ability of other soluble and matrix
components to decrease IL-6 production by MCs needs to be
better defined.
In vivo studies
The aforementioned in vitro studies have established that
cultured mesangial cells proliferate in response to IL-6 and
produce IL-6 both constitutively and following stimulation by a
wide array of autocrine and paracrine factors. A growing body
of evidence suggests that the observations in vitro may be
similar to what occurs in vivo. The first evidence that overpro-
duction of IL-6 may lead to mesangioproliferative glomerulo-
nephritis was obtained in the transgenic mouse model discussed
earlier [1]. The data of Horii et al [81 expanded these observa-
tions. Using a monoclonal anti-IL-6 antibody, IL-6 was local-
ized to the mesangial cells in affected glomeruli of patients with
proliferative glomerulonephritis. Glomeruli from patients with
membranous nephropathy, minimal change disease, or normal
individuals did not exhibit increased IL-6 using this approach
[8]. Similar data have also been obtained by Fukatsu et al [13]
using indirect immunofluorescence with a monoclonal anti-
human IL-6 antibody. The intensity of IL-6 staining correlated
with an increase in glomerular cell number [13]. These data
strongly suggest that proliferative glomerulonephritis is associ-
ated with higher levels of IL-6 in the affected glomeruli. The
findings, however, do not firmly establish whether the mesan-
gial cells are the source of the IL-6 or whether proliferating
mesangial cells bind more exogenous IL-6.
Further elucidation of the role of IL-6 in mesangial prolifer-
ation in vivo was obtained by measuring urinary IL-6 levels [8].
Urine from normal patients and patients with minimal change
nephropathy did not contain measurable IL-6 levels. Urinary
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Table 3. Summary
Characterization of MC-derived IL-6
1. Interleukin-6 is produced by mesangial cells (MCs) in vitro.
2. Biochemical properties of MC-derived LL-6 are similar to IL-6
from other sources.
3. IL-6 production by MCs is increased by several
proinflammatory cytokines and bacterial lipopolysaccharide,
but is decreased by type I collagen.
Interleukin-6 is an autocrine growth factor for MCs
in vitro
I. IL-6 induces growth of rat MCs in the presence of serum
in vivo
1. Urinary IL-6 levels may correlate with both the presence and
severity of proliferative glomerulonephritis.
2. The level of IL-6 in the glomerulus may be correlated with the
number of glomerular cells.
IL-6 was detected in 2 of 27 patients with membranous
nephropathy. In contrast, 19 of 38 patients with proliferative
glomerulonephritis contained detectable levels of IL-6 in the
urine. Of further interest, urinary IL-6 levels were higher in the
patients with more advanced proliferative lesions than in those
with mild disease [811. Although urinary creatinine was not
measured as a control, urinary IL-i levels were not significantly
different between the four patient groups.
The possibility that decreased IL-6 levels may be associated
with states of reduced glomerular cellularity is supported by the
observation that IL-6 binding was decreased in glomeruli with
advanced sclerosis [13]. These data from in vivo studies are
consistent with our observations which suggest that IL-6 pro-
duction by mesangial cells in vitro is decreased by extracellular
matrix components such as type I collagen.
The data supporting the role of IL-6 as an autocrine regulator
of mesangial cell growth are summarized in Table 3. The
available studies have provided a compelling basis for several
areas of future investigation, Additional studies are urgently
needed to further characterize the effect of IL-6 in mesangial
cell function and to define the molecular events which regulate
IL-6 production and mediate its effects on mesangial cells.
Extrapolation of data from these studies in vitro to mesangial
cells in vivo must take into account the complex interdepen-
dence of cytokine networks which regulate cell physiology,
These studies will serve as an important foundation for the
design of therapeutic strategies to regulate the function and
growth of cells in the glomerular mesangium.
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